Kevin Hamblett is a Senior Director at Pfizer, specializing in antibody drug conjugates within the oncology biotech industry. With over 20 years of experience, they have successfully led research programs from discovery through IND and developed innovative therapeutic strategies by exploring novel biological aspects. Previously, they held senior positions at companies such as Seagen, Zymeworks Inc., and Amgen, where they directed teams and advanced numerous projects, including bispecific antibodies and antibody-drug conjugates. Kevin earned a BS and a PhD in Bioengineering from Syracuse University and the University of Washington, respectively.
This person is not in any teams
This person is not in any offices